The weekend of March 10, 2022 we will be holding two Forums at the beautiful Asilomar Conference Grounds in Pacific Grove, California!
Neuroendocrine Cell Fate in Development and Cancer will be chaired by Cory Abate-Shen, PhD of Columbia University and Julien Sage, PhD of Stanford University.
Neuroendocrine cancer is an umbrella term for a group of tumors in which cancer cells have the particularity of displaying traits similar to those of both nerve cells and hormone-producing cells. Neuroendocrine tumors can occur in many tissues and organs in the human body, including the lung, the pancreas, the prostate, or the skin. Some neuroendocrine tumors are very rare, others are more frequent; some are indolent, while others are extremely aggressive and fatal. Historically, neuroendocrine tumors have been studied and treated in the context of the specific site in which they were found. More recently, however, accumulating evidence has indicated that neuroendocrine tumors from various sites shared a number of important features, especially in terms of oncogenic drivers. A major goal of the meeting will thus be to discuss the biology and clinical aspects of neuroendocrine tumors to understand the differences and similarities between these tumors in different organs and tissues. We hope to identify a framework to develop future therapeutic strategies that may help all patients with neuroendocrine cancer.
To learn more about this forum and it's participants, please visit forbeckforums.org.
Challenges and Opportunities for Transformative Therapeutic Development for Ovarian Cancer will be chaired by Daniela Matei, MD of Northwestern University and Kenneth P. Nephew, PhD of Indiana University.
Ovarian cancer is one of the most aggressive cancers and a major cause of cancer morbidity and mortality in women. Poor outcomes relate, in part, to lack of adequate screening procedures, late stage at initial diagnosis, intrinsic or acquired drug resistance, and the propensity to disseminate widely intra-peritoneally. These traits render ovarian cancer one of the most challenging diseases to manage, with cytoreductive surgery and combination platinum-based chemotherapy having remained the mainstays of treatment. However, in the past few years, the completing of the TCGA analysis led to a new molecular classification of ovarian tumors and novel therapeutic strategies advanced to the forefront. Although there are now more than 280,000 ovarian cancer survivors in the United States, long-term survival in late-stage disease has improved little over the last four decades.
To learn more about this forum and it's participants, please visit forbeckforums.org.
